The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As an observation. The lead researchers for the trials are uk based. The eu expansion of trials was primarily ovarian which seems to be duff. From the uk trials database i think the mono trial has finished. I think the combo is extended in existing patients as some benefit. Rmm excellent in market size on anogenital. But IF positive with few rival options 10p to a quid on chk1. Lets hope they dont bury the data for too long. (1bn sales anal cancer. 27m pa royalty to sar =10p) fagpacket calcs. Anogenital =16bn pa plus any combo options. Sitting happy
March 12th rns additional indications, all positive then. silence since then, must be deal being negotiated, which take at least 6 months haggling normally.
6+3= phase 3
whatever is going on behind closed doors, news must be imminent. Even if they keep the trials in house, but my gut feeling as others here is now Gilead, just hope we don't get screwed over in the small print..
come on sierra, break the silence, before news is leaked....
It depends on number of indications and other variables. Usually milestones double at each stage with the biggest when approved for sale. However. With few treatments for anogenital cancer. I believe they may have a strong case for approval on completion of phase2. Which would accelerate milestones but also royalties. I suspect thats behind the delay and dillying (no pun intended) by sierra. They can see the data we cant yet.
Any idea what value milestones could be triggered for p3 trials to sareum?
5, 7,10,20mil??
88mil was in the pot for Sareum!
Any idea what value milestones could be triggered for p3 trials to sareum?
5, 7,10,20mil??
328.5mil was in the deal at 25% for sareum = 82.125mil
so going forward with SRA737, unless I'm reading the progress wrong, next step It will be heading into phase 3 trials! :)
As I understand, the trials have finished but if there are patients benefitting from the treatment then the treatment will continue which just go to show the effectiveness of the Chk 1 inhibitor. This beneficial treatment has been going on for months now.
Is the information rehashed from the interview, or was anything new highlighted?
308...
It was dated 3 days ago, do we know how current the information on it is? Only asking as it claims that SRA737 is: (and I quote)
“It is currently undergoing two Phase II clinical trials in patients with advanced cancer – one as monotherapy and another in combination with low-dose gemcitabine, which is one of the most commonly-prescribed chemotherapies.”
I know there was some discussion on here in the last week or 2 as to wether SRA737 is still being trialed, or if it had ended? Great news if it’s still in trials
good find BB'' that link was 3 days ago that's currant...
Sareum also said it expects to hear in October the response to a grant request to fund work on TYK2/JAK1 inhibitors to treat coronavirus (COVID-19) symptoms.
so the BOD at long last have got an official month of October for that grant to come through
and that's just a few days away... UMMMM indeed''
we could soon start seeing the rise back to 0.94p as investor start taking there position
on the thought of a good result for the COVID 19 GRANT, and SRA737 finally getting the funding
to take it to market ASAP, or a big fat wallet taking it over from them wasters with no reason but to leave it
on the shelf although they know how good it is.. we know it is not the money with SIERRA
because they just got new funding of $120m to waste on a stage 3 that don't work and need a lot of tweaking
before it gets to market... perhaps they have there reason and are leaving it on the shelf
and see what the competition comes up with first, and watch SRA737 rise in value who @knows?
GLA
308..